Cost-Effectiveness Analysis of Consolidation With Brentuximab Vedotin for High-Risk Hodgkin Lymphoma After Autologous Stem Cell Transplantation

Cancer - United States
doi 10.1002/cncr.30818
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Brentuximab Vedotin Salvage Followed by Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in High Risk Relapsed Refractory Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Improving Outcomes After Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma in the Brentuximab Vedotin Era

Bone Marrow Transplantation
TransplantationHematology
2017English

BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Real-World Effectiveness of Brentuximab Vedotin Versus Physicians’ Choice Chemotherapy in Patients With Relapsed/Refractory Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the United Kingdom and Germany

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2017English

Brentuximab Vedotin Prior to Allogeneic Stem Cell Transplantation in Hodgkin Lymphoma: A Report From the EBMT Lymphoma Working Party

British Journal of Haematology
Hematology
2018English

Treatment Pathways and Resource Use Associated With Recurrent Hodgkin Lymphoma After Autologous Stem Cell Transplantation

Bone Marrow Transplantation
TransplantationHematology
2017English

A Cost-Effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Journal of Health Economics and Outcomes Research
2016English

The Aethera Trial: An Ongoing Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma Following Autologous Stem Cell Transplant

Biology of Blood and Marrow Transplantation
TransplantationHematology
2014English

Pcn175 - Brentuximab Vedotin Compared With Standard Therapy for Patients With Advanced-Stage Hodgkin’s Lymphoma: A Cost-Effectiveness Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy